Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Pharmaceutical industry ethical issues

In short, we return to C. P. Snow s recommendation that the scientist and humanist converse more. The conversations, analysis, and discussion should include the third culture, the technologist. Therefore, although we have not provided specihc and detailed analysis of issues related to computer use in the pharmaceutical industry, believing as we do that that sort of analysis is for the specialized philosopher doing conceptual analysis in computers ethics, we do urge that applied philosophers be part of the research team. Also, in the dynamic and flexible world of technology, applied philosophers—not just the people in the held of computers—should help draft policy statements and codes of conduct. [Pg.724]

In in vivo studies, an important issue is the quality of ECG recordings and the methods used for the analysis. A few years ago, a survey reported on the practice in the pharmaceutical industry to assess the potential for QT prolongation and concluded that the majority view in the industry is not necessarily best practice [153]. After this publication, a lot of work has been done to improve the performance of in vivo models, although it should be acknowledged that their cost (together with some ethical considerations on the rational use of animals) makes them unsuitable for large-scale screening. [Pg.71]

This high attrition rate, particularly during late preclinical and clinical development, carries a large price tag for the pharmaceutical and biotechnology industry, which is carried over to health care providers. In addition, compounds which qualify for clinical use but fail due to safety matters raise serious ethical issues and questions concerning the responsibility and competence of the industry and registration authorities. [Pg.530]

Komesaroff, P. A. and I. H. Kerridge. 2002. Ethical Issues Concerning the Relationships between Medical Practitioners and the Pharmaceutical Industry. The Medical Journal of Australia 176 118-121. [Pg.64]

Patents in the Pharmaceutical Biotechnology Industry Legal and Ethical Issues... [Pg.187]

This chapter will provide the reader with an overview of patenting in the pharmaceutical biotechnology industry and summarize some of the key legal and ethical issues related to the patenting of biomedical products and processes. It will examine the legal aspects of patenting before considering the ethical and policy issues. This essay will focus primarily on the U S patent laws, which are very similar to the European patent laws. The essay will note some differences between the US and European laws, and it will mention some relevant international intellectual property treaties. [Pg.187]

The aim of this chapter is to describe the general framework for conducting good clinical practices (GCP)-compliant clinical research, particularly pharmaceutical industry clinical research. Since it is difficult to cover this broad topic in such a short chapter, the authors will focus on those areas that are most discussed, most problematic, and most critical to achieving a GCP-compliant clinical study. Thus, there is particular emphasis on ethical issues, source data verification and data integrity, monitoring and safety review, and study medica-tion/device management. [Pg.69]

This paper sets out to show, within the vagaries of the pharmaceutical industry, the CAPE tools that can be used in process development. There are a number of issues to be resolved when developing a process, not just process specific, but business (economic) drivers, safety issues, environmental concerns, moral and ethical issues and regulatory requirements. In light of these varied challenges, we have found that not one CAPE package covers every aspect of development and that the combination of a number of specific tools suits the requirements of the pharmaceutical industry. [Pg.1090]

The chapters in Part III therefore tease out experiences of some of the key aspects of health-industry interactions in more detail and identify some important policy issues to be tackled. All these issues are framed by political economy considerations of the ethics, interests and institutions involved. They include the highly contentious matters of price controls and standard setting for pharmaceutical products, plus examination of sources and problems of financing, the scope for innovative procurement processes that can reflect health system values while providing incentives for industrial investment, and the contested but important role of industrial manufacturers associations and political lobbying. [Pg.3]


See other pages where Pharmaceutical industry ethical issues is mentioned: [Pg.726]    [Pg.77]    [Pg.101]    [Pg.360]    [Pg.386]    [Pg.64]    [Pg.275]    [Pg.167]    [Pg.170]    [Pg.182]    [Pg.232]    [Pg.2]    [Pg.23]    [Pg.8]    [Pg.23]    [Pg.282]    [Pg.302]    [Pg.314]    [Pg.314]    [Pg.36]    [Pg.8]    [Pg.347]    [Pg.459]    [Pg.160]    [Pg.651]   
See also in sourсe #XX -- [ Pg.383 , Pg.384 , Pg.385 , Pg.386 ]




SEARCH



Ethical issues

Ethics pharmaceutical industry

Pharmaceutical industry

© 2024 chempedia.info